Myriad Women's Health provides the following resources in select languages:

Myriad Foresight® Carrier Screen Spotlight

Congenital Adrenal Hyperplasia

CYP21A2-Related (21-OH CAH)

What is CAH?

Congenital adrenal hyperplasia (CAH) is a family of conditions affecting hormone levels. The most common form of CAH, 21-hydroxylase-deficient congenital adrenal hyperplasia (21-OH CAH), is caused by mutations in the CYP21A2 gene. Symptoms of 21-OH CAH include:

  • Failure to thrive
  • High blood pressure
  • Life-threatening sodium deficiency
  • Hormone imbalances
  • Fertility issues

Michèle and Maris

“My pediatrician told me that if I didn’t bring my son in… we likely would have lost him.”
Michèle, carrier for 21-OH CAH 

Although her son Maris (age 6) appeared healthy after birth, a few days later Michèle could tell something was wrong. She first heard about CAH when her son was being treated in the emergency room, and is passionate about ensuring families have access to information that could prove vital in saving their child’s life.

Did you know?

Advance knowledge of hereditary conditions like 21-OH CAH can inform life-saving intervention after birth and prevent the diagnostic odyssey, saving years of stress, anxiety and cost

21-OH CAH is similar in incidence to spinal muscular atrophy, for which universal screening guidelines exist

Due to technical challenges, 21-OH CAH is absent from most expanded carrier screening panels

Every couple deserves insight

The Foresight Carrier Screen is methodically designed to maximize the detection of couples at-risk for a pregnancy affected by serious, prevalent inherited conditions such as 21-OH CAH.³

In total, ~1 in 300 pregnancies are affected by a condition on the Foresight Carrier Screen.²

Expect more

21-OH CAH is absent from most carrier screening panels because it is technically challenging to test for and requires more advanced analysis to avoid false positives and false negatives. Myriad’s custom assay for 21-OH CAH maximizes detection rates that give you the utmost confidence in every result.

“"I've always said that if you can name it, you can do something about it."”
Allison Landa, Patient living with 21-OH CAH

Watch our Recorded Webinar

Learn more about the impact of 21-OH CAH on affected individuals and how screening can help improve outcomes.

References:

1. Nimkarn S, et al. (Updated 2016 Feb 4). In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® (Internet). Seattle (WA): University of Washington, Seattle; 1993- 2018. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1171/.
2. Hogan GJ. et al. Clin Chem 2018; doi:10.1373/clinchem.2018.286823
3. Beauchamp KA, Muzzey D, Wong KK, et al. “Systematic design and comparison of expanded carrier screening panels” Genetics in Medicine 2017; doi:10.1038/gim.2017.69